These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31317313)

  • 1. Behçet's syndrome: focus on pathogenetic background, clinical phenotypes and specific treatments.
    Emmi G; Prisco D
    Intern Emerg Med; 2019 Aug; 14(5):639-643. PubMed ID: 31317313
    [No Abstract]   [Full Text] [Related]  

  • 2. A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Behçet's disease in HLA-B*51 carriers.
    Takeuchi M; Ombrello MJ; Kirino Y; Erer B; Tugal-Tutkun I; Seyahi E; Özyazgan Y; Watts NR; Gül A; Kastner DL; Remmers EF
    Ann Rheum Dis; 2016 Dec; 75(12):2208-2211. PubMed ID: 27217550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of Behçet's syndrome with HLA-B51 as understood in 2021.
    Takeno M
    Curr Opin Rheumatol; 2022 Jan; 34(1):4-9. PubMed ID: 34690278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetics of Behçet's disease: lessons learned from genomewide association studies.
    Gül A
    Curr Opin Rheumatol; 2014 Jan; 26(1):56-63. PubMed ID: 24257369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pathogenic concepts, nosological limits and diagnostic criteria of Behçet's disease].
    Hamza M
    J Mal Vasc; 1988; 13(3):250-6. PubMed ID: 3049884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1.
    Kirino Y; Bertsias G; Ishigatsubo Y; Mizuki N; Tugal-Tutkun I; Seyahi E; Ozyazgan Y; Sacli FS; Erer B; Inoko H; Emrence Z; Cakar A; Abaci N; Ustek D; Satorius C; Ueda A; Takeno M; Kim Y; Wood GM; Ombrello MJ; Meguro A; Gül A; Remmers EF; Kastner DL
    Nat Genet; 2013 Feb; 45(2):202-7. PubMed ID: 23291587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and environmental factors in the development of Behcet's disease.
    Tanaka K; Kajiyama K; Imamura T; Jimi S; Watanabe T; Sato H; Okochi K; Inoue T
    Tohoku J Exp Med; 1985 Feb; 145(2):205-13. PubMed ID: 3857725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A genetic study of Behçet's disease in Taiwan Chinese.
    Chung YM; Tsai ST; Liao F; Liu JH
    Tissue Antigens; 1987 Aug; 30(2):68-72. PubMed ID: 3672493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Behçet's disease].
    Hamza M
    Rev Med Interne; 1989; 10(4):299-301. PubMed ID: 2552551
    [No Abstract]   [Full Text] [Related]  

  • 10. HLA antigens in a family with Behçet's syndrome.
    Fallingborg J; Ambrosius Christensen L; Grunnet N
    Acta Med Scand; 1986; 220(4):375-8. PubMed ID: 3799242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behçet's disease: an update on the pathogenesis.
    Gül A
    Clin Exp Rheumatol; 2001; 19(5 Suppl 24):S6-12. PubMed ID: 11760403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serological and molecular HLA typing in Andalusian patients with Behçet's disease. Genetic-clinical correlations].
    Román JA; Puig N; Tornero C; Alcañiz C
    Med Clin (Barc); 1997 Mar; 108(10):397-8. PubMed ID: 9139150
    [No Abstract]   [Full Text] [Related]  

  • 13. The Behçet's disease-associated variant of the aminopeptidase ERAP1 shapes a low-affinity HLA-B*51 peptidome by differential subpeptidome processing.
    Guasp P; Barnea E; González-Escribano MF; Jiménez-Reinoso A; Regueiro JR; Admon A; López de Castro JA
    J Biol Chem; 2017 Jun; 292(23):9680-9689. PubMed ID: 28446606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behçet's disease: An immunogenetic perspective.
    Salmaninejad A; Zamani MR; Shabgah AG; Hosseini S; Mollaei F; Hosseini N; Sahebkar A
    J Cell Physiol; 2019 Jun; 234(6):8055-8074. PubMed ID: 30341905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of the 'Mis-Peptidome' on HLA Class I-Mediated Diseases: Contribution of ERAP1 and ERAP2 and Effects on the Immune Response.
    Tedeschi V; Paldino G; Paladini F; Mattorre B; Tuosto L; Sorrentino R; Fiorillo MT
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of immune responses associated with ERAP-1 expression in HSV-induced Behçet's disease mouse model.
    Ryu HM; Islam SMS; Sayeed HM; Babita R; Seong JK; Lee H; Sohn S
    Clin Immunol; 2023 May; 250():109305. PubMed ID: 37003592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epistatic Interaction of ERAP1 and HLA-B*51 in Iranian Patients with Behçet's Disease.
    Mahmoudi M; Ashraf-Ganjouei A; Javinani A; Shahram F; Meguro A; Mizuki N; Ahmadzadeh N; Jafarinejad-Farsangi S; Mostafaei S; Kavosi H; Faezi ST; Akhlaghi M; Davatchi F
    Sci Rep; 2018 Dec; 8(1):17612. PubMed ID: 30514861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnosis of Behçet's syndrome].
    Dührsen U; Kirch W
    Dtsch Med Wochenschr; 1985 Feb; 110(7):264-7. PubMed ID: 3971875
    [No Abstract]   [Full Text] [Related]  

  • 19. ERAP1 polymorphisms interactions and their association with Behçet's disease susceptibly: Application of Model-Based Multifactor Dimension Reduction Algorithm (MB-MDR).
    Riahi P; Kazemnejad A; Mostafaei S; Meguro A; Mizuki N; Ashraf-Ganjouei A; Javinani A; Faezi ST; Shahram F; Mahmoudi M
    PLoS One; 2020; 15(2):e0227997. PubMed ID: 32023277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-B51 may serve as an immunogenetic marker for a subgroup of patients with Behçet's syndrome.
    Chajek-Shaul T; Pisanty S; Knobler H; Matzner Y; Glick M; Ron N; Rosenman E; Brautbar C
    Am J Med; 1987 Oct; 83(4):666-72. PubMed ID: 3314492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.